The androgen receptor (AR) is one of the most studied and therapeutically targeted oncogenes in prostate cancer, but androgen deprivation therapy (ADT), as well as AR signaling inhibitors, frequently lead to alterations of AR expression or post-translational modifications, resulting in resistance to therapy over time, occurring via multiple mechanisms that are still undergoing investigation [2]. This evidence concerns the gene AR and prostate carcinoma.